MEN 1611
Alternative Names: CH-5132799; MEN-1611; PA-799Latest Information Update: 27 May 2024
At a glance
- Originator Chugai Pharma Europe
- Developer Berlin Chemie; Chugai Pharma Europe; Menarini Ricerche
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer; HER2 negative breast cancer
- No development reported HER2 positive breast cancer; Solid tumours
Most Recent Events
- 27 Feb 2024 Menarini Ricerche completes a phase-I/II clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Germany (PO) (NCT04495621)
- 23 Feb 2024 Menarini Group completes phase I B-PRECISE-01 trial in Her2 positive Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA, United Kingdom, France, Belgium, Spain and Italy (PO) (NCT03767335)
- 28 Nov 2023 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium (PO)